Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Rectal Cancer: early-phase trial registry
32 of 72 indexed Rectal Cancer trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #191 of 28,707 conditions by registered trial count.
72 US clinical trials · 32 currently recruiting · #191 of 28,707 conditions by registered trial count
Rectal Cancer: 72 US clinical trials tracked, 32 recruiting.
Rectal Cancer is the subject of 72 registered US clinical trials on ClinicalTrials.gov, 32 of them currently open to new participants. 4 are in Phase 3-4 (later-stage) and 31 in Phase 1-2 (earlier-stage). The most active sponsor is Memorial Sloan Kettering Cancer Center, running 8 of these trials.
Enrollment posture brief
Registry condition rectal-cancer
OPEN 32 | RECR 44% | LATE 4 | EARLY 31 | RANK #191 | SPON 8
Volume-matched condition peers
Nearest open-share peer: Acute Ischemic Stroke (44% recruiting · 27 trials)
Rectal Cancer lists 32 open slots (44% of 72 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Rectal Cancer on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Rectal Cancer is recruiting above its size-band peers.
32 of 72 indexed trials (44.4%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Rectal Cancer trials is spread across many organizations.
Memorial Sloan Kettering Cancer Center accounts for 8 of 72 trials (11.1%). 48 distinct sponsors appear on at least one study for this condition label.
-
Most Rectal Cancer trials plan to enrol fewer than 100 people.
Median target enrolment is 54 among the 71 trials that report a genuine target (sentinel values excluded). 44 of those (62%) plan for fewer than 100 participants.
-
Rectal Cancer research is mostly interventional.
58 interventional and 14 observational studies make up this index (80.6% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
72 total, page 2 of 2
Negative Pressure Therapy in Preventing Infection After Surgery in Patients With Colon, Rectal, Pancreatic, or Peritoneal Surface Cancer
Wake Forest University Health Sciences
NCT01656044
Patient Activation Intervention in Improving Screening Rates for Colorectal Cancer
Ohio State University Comprehensive Cancer Center
NCT01801059
A Study of LY2880070 in Participants With Advanced or Metastatic Cancer
Esperas Pharma
NCT02632448
Phase 1b/2 Study of AMG 655 With mFOLFOX6 and Bevacizumab for First-Line Metastatic Colorectal Cancer
Amgen
NCT00625651
The Sexual Health of Rectal Cancer Patients
Memorial Sloan Kettering Cancer Center
NCT00712751
GI SPORE Colon Biosample Protocol
University of Michigan
NCT02243267
Evaluating The Response to Pre-Operative Chemotherapy and/or Radiation Therapy For Rectal Cancer Using Three-Dimension Transrectal Ultrasound
Memorial Sloan Kettering Cancer Center
NCT00597610
An Assessment of Goal-Directed Intraoperative Fluid Management in Hand Assisted Laparoscopic Colectomy
Corewell Health West
NCT00467922
5-Fluorouracil, Bevacizumab, and Radiation Followed by Modified FOLFOX6 and Bevacizumab in Stage II/III Rectal Cancer
SCRI Development Innovations
NCT00308516
Computer-Based Comprehensive Geriatric Assessment in Oncology for Individuals 70 or Older With Gastrointestinal Malignancies
Dana-Farber Cancer Institute
NCT00973440
CB-839 + Capecitabine in Solid Tumors and Fluoropyrimidine Resistant PIK3CA Mutant Colorectal Cancer
David Bajor, MD
NCT02861300
Clinical Trial in Patients With Metastatic Colorectal Cancer
Mast Therapeutics
NCT00081627
Promoting Physical Activity After Colorectal Cancer
The Miriam Hospital
NCT00230646
5-FU, Aflibercept, and Radiation (RT) for Preoperative and Postoperative Patients With Stage II/III Rectal Cancer
SCRI Development Innovations
NCT01749956
Neoadjuvant Chemoradiation With RHUMAB VEGF (Avastin) for Rectal Cancer
M.D. Anderson Cancer Center
NCT00113230
Non-Operative Radiation Management of Adenocarcinoma of the Lower Rectum
Washington University School of Medicine
NCT02641691
Clinical and Translational Study of STA-9090
Memorial Sloan Kettering Cancer Center
NCT01111838
Cellular Immune Augmentation in Colon and Rectal Cancer
University of California, Irvine
NCT00257322
Physical Activity in Rectal Cancer Survivors
Abramson Cancer Center at Penn Medicine
NCT06435975
Phase I Trial of Ganetespib, Capecitabine, and Radiation in Rectal Cancer
Emory University
NCT01554969
Rectal Cancer Consortium
Brown University
NCT01835925
Molecular Determinants Affecting Fluoro-L-thymidine (FLT) Positron Emission Tomography (PET) in Rectal Cancer
Vanderbilt-Ingram Cancer Center
NCT01207895
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 12 |
| Phase 2 | 19 |
| Phase 3 | 4 |
Top Sponsors
Named interventions
Most-linked intervention names on Rectal Cancer records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Rectal Cancer trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Rectal Cancer page
72 registered trials, 32 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 32 Rectal Cancer trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Memorial Sloan Kettering Cancer Center sponsors the most Rectal Cancer trials on record, review their full trial history before evaluating a specific study. See Memorial Sloan Kettering Cancer Center's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Rectal Cancer condition card totals 72 registered trials; most-linked intervention Leucovorin; top US site state New York. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.